April Sees Surge in Medical Sector Funding: Multiple Companies Secure Hundreds of Millions in Financing

　　【Pharmaceutical Network Industry DynamicsSince April 2026, multiple companies in the medical field have announced the completion of new financing at the hundred-million level. Among them, the cardiovascular intervention track and ophthalmic medical device track have performed particularly well.
 

Recently, Pulnovo Medical announced the completion of its $100 million Series D financing round, led by Medtronic, with continued participation from existing investors EQT, Qiming Venture Partners, Gao Rong Capital, Orbimed, and Lilly Asia Ventures.
 

Data shows that the Pulmonary Artery Denervation (PADN) system, independently developed by Pulnovo Medical, is a minimally invasive interventional therapy product. This therapy has been included in several international clinical guidelines, including the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. In addition, multiple clinical studies are also being simultaneously advanced in various regions worldwide.
 

The funds from this round of financing will be used to support ongoing clinical research and development, global regulatory submissions, international commercialization efforts, and continued investment in core technology platforms. Through this financing, Pulnovo Medical will further deepen its strategic collaboration with global industry and capital partners. Additionally, the company’s comprehensive capabilities in advancing clinical R&D, global strategic deployment, and expanding commercial operations will be enhanced.
 

On April 20, FemtoMarch Medical announced the completion of nearly 100 million yuan in angel round financing. The funds will be used for product technology iteration and upgrades, clinical trials, animal experiments, etc.
 

It is reported that after this round of financing, FemtoMarch Medical will accelerate the registration and clinical trials of femtosecond refractive products while ensuring the ultra-high performance and quality of super high-end medical equipment, in order to obtain medical device registration certificates both in China and internationally as soon as possible. At the same time, the company will also expedite the research and development of other ophthalmic diagnosis and treatment products to improve the entire refractive industry chain.
 

April 8, Moptim announced the completion of a nearly 100-million-yuan B-round financing. The funds from this round will be used for the iteration of underlying optical core technologies, expansion of high-end manufacturing capacity, upgrade of AI algorithms, and to promote the large-scale implementation of products in grassroots healthcare in China and the global market.
 

After this round of financing, Moptim will focus on three key areas for high-quality development: core technology breakthroughs, expansion of high-end manufacturing, and global strategic deployment. In terms of core technology, the company will continue to enhance its capabilities in high-resolution imaging, high-speed scanning, and AI-assisted analysis, reinforcing its self-developed core competitive edge in China.
 

April 7th, Conmind Medical completed nearly 200 million yuan in its C-round financing. Public information shows that it is a high-tech enterprise focusing on the research, development, production, and sales of cardiovascular and cerebrovascular diagnosis and treatment products. Through minimally invasive interventional technology and brain-computer interface platforms, it has built a full-cycle solution for brain medical diseases covering "prevention, treatment, and functional reconstruction."
 

This round of financing will focus on the research and development of core brain-computer interface technologies, iteration of key components, and industrialization layout. It aims to overcome technical barriers, accelerate product implementation, and promote the large-scale clinical application of the technology, injecting strong capital momentum into the company's next stage of rapid development.
 

　　Disclaimer: Under no circumstances shall the information or opinions expressed in this article constitute investment advice to any person.